New therapeutics that harness cellular machinery to degrade targets are entering clinical trials, led by a PROTAC anticancer candidate developed by Arvinas.
Whereas most small molecules inhibit a protein’s activity by blocking its active site, Arvinas is on the hunt for small molecules dubbed ‘PROTACs’ that could co-opt the cell’s degradation machinery to break the proteins down entirely.